Biopharmaceutical News and Research

RSS

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Repligen acquires BioFlash

Repligen Corporation announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.

4 Mar 2010

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with Harvard University and the Howard Hughes Medical Institute to provide their researchers with the LEAP™ Cell Processing Workstation.

3 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

The Greffex Group of regenerative medicine companies announces the signing of a Strategic Alliance Framework Agreement with UPMC and ISMETT, Italy.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.

1 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Pi2 Solutions introduces 2010 version of Product Literature Database System

Pi2 Solutions announces the all-new 2010 version of their world-leading Product Literature Database System. This versatile application builds on the success of the 2003 version in use in biopharmaceutical companies around the globe.

1 Mar 2010

Eli Lilly, Covance announce key milestones of their first-year partnership

Senior executives from Eli Lilly and Company and Covance Inc. announced Friday that the first year of their landmark alliance has been a win-win for both companies, enabling Lilly to expedite the flow of innovation within its pipeline in order to provide improved outcomes for individual patients.

27 Feb 2010

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Medical innovation and research: A real boon for American patients to live longer, healthier

An article in the Suislaw News recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

26 Feb 2010

UCB adopts Enterprise version of NextBio platform

NextBio, developer of an innovative software platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced a license agreement with global biopharmaceutical company UCB, for NextBio Enterprise. NextBio Enterprise offers life sciences organizations unique tools for knowledge discovery and collaboration, seamless integration of internal and external research data, and secure data access.

26 Feb 2010

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

25 Feb 2010

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere’s Convertible Promissory Note to May 26, 2010.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Biopharmaceutical News and Research

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Repligen acquires BioFlash

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

Archimedes Pharma raises GBP65 million in new funding

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Pi2 Solutions introduces 2010 version of Product Literature Database System

Eli Lilly, Covance announce key milestones of their first-year partnership

Shire receives marketing approval from FDA for VPRIV

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Medical innovation and research: A real boon for American patients to live longer, healthier

UCB adopts Enterprise version of NextBio platform

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Pittcon Highlights: Pharmaceutical & Biologic eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News